Please assess the completion status of the following clinical trial:

Trial Title: A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Criteria for entering this study will include all of the following:~1. Subjects must be 18 years of age or older.~2. Subjects must have schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, psychotic disorder NOS, or bipolar I, II, or NOS disorder as defined by DSM-IV-TR criteria.~3. Subjects must have a BMI \> 22.~4. Subjects must sign the Informed Consent Document after the nature of the trial has been fully explained.~5. If female, subjects must be: postmenopausal, surgically incapable of childbearing, or practicing medically acceptable effective method(s) of contraception (e.g., hormonal methods, intrauterine device) for at least one month prior to study entry and throughout the study.~6. If exposed to olanzapine in the past, subjects must be free of olanzapine for \> 3 months prior to randomization to study medication.~Exclusion Criteria:~Criteria for exclusion from this study will be any of the following:~1. Subjects with clinically significant suicidal or homicidal ideation.~2. Subjects with a current DSM-IV Axis I diagnosis of delirium, dementia, amnesia, or other cognitive disorders; a psychotic or mood disorder secondary to substance use or a general medical disorder; or a DSM-IV diagnosis of a substance use disorder within the past six months.~3. Cardiovascular, endocrine, neurologic, or hematologic disease as determined by the clinical judgment of the clinical investigator. Subjects with hypo- or hyperthyroidism unless stabilized on thyroid replacement \> 3 months.~4. Subjects who are allergic to or who have demonstrated hypersensitivity to or significant adverse event from olanzapine.~5. Subjects who are allergic to or who have demonstrated hypersensitivity to zonisamide.~6. Women who are pregnant or nursing.~7. Subjects who have received an experimental drug or used an experimental device within 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugar pill (Type: EXPERIMENTAL): olanzapine and placebo (sugar pill)
- Zonisamide (Type: EXPERIMENTAL): olanzapine and zonisamide (active drug)

Based on this trial design, predict the completion outcome and termination type (if applicable).